Drugs / rindopepimut
rindopepimut
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01058850 | Jun 2011 → Sep 2013 | brain cancer, brainstem neoplasm | Paul Graham Fisher | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01498328 | Dec 2011 → Apr 2015 | giant cell glioblastoma, gliosarcoma | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00458601 | Aug 2007 → Nov 2010 | malignant glioma | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01480479 | Nov 2011 → Nov 2016 | giant cell glioblastoma, gliosarcoma, mixed astrocytoma-ependymoma-oligodendroglioma | Celldex Therapeutics | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03068650 | — | glioblastoma | Celldex Therapeutics | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rindopepimut | “Rindopepimut consists of the unique EGFRvIII peptide sequence conjugated to keyhole limpet hemocyanin.” PMID 25586468 ↗ Jan 2015 |
| Known as | CDX-110 | “Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin.” PMID 28844499 ↗ Aug 20172“A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.” PMID 25586468 ↗ Jan 2015 “Rindopepimut (CDX-110) with GM-CSF” NCT01498328 ↗ |
| Known as | PF-04948568 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107863 ↗ |
| Known as | PF-04948568 (FORMERLY CDX-110) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107863 ↗ |
| Modality | Vaccine | “rindopepimut vaccination” PMID 25586468 ↗ Jan 2015 |
| Target | EGFR | “a vaccine targeting the EGFR deletion mutation EGFRvIII” PMID 28844499 ↗ Aug 2017 |